Nivolumab (Opdivo, Bristol-Myers Squibb) with platinum-based chemotherapy as neoadjuvant treatment then alone as adjuvant treatment after surgical resection is indicated for 'the treatment of adults with resectable (tumours ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements'.
The dosage schedule is available in the summary of product characteristics for nivolumab.
The list price is £439 per 40 mg/4 ml vial (excluding VAT; BNF online accessed November 2025). A full course of neoadjuvant treatment is £3,951 over 12 weeks and a full course of adjuvant treatment is £5,268 over 1 year (excluding VAT; company submission).
The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Bristol-Myers Squibb's webpage on sustainability.